Reference, not advice. Rapamycin (sirolimus) is a prescription immunosuppressant. Its use for longevity is off-label and unproven in humans. This page describes what the evidence shows. It publishes no doses, gives no guidance on use, and does not replace a prescriber. Vallydia does not sell, supply or link to rapamycin.
Rapamycin has the strongest lifespan data of any compound in our register, and it has a grade F for human longevity. Both grades are correct.
The distance between those two letters is the whole story of rapamycin.
Longevity forums speak of rapamycin as proven. The proof they mean is real – but it was obtained in mice. In 2009 the US National Institute on Aging's Interventions Testing Program published in Nature that rapamycin, fed to genetically diverse mice late in life, extended their lifespan. The result was replicated at three sites. No other drug has managed it from a late-life start.
Moving from "works in mice" to "works in people" is the step that has failed for most of gerontology. For rapamycin, that step has not been taken yet.
| Outcome | Grade | Basis |
|---|---|---|
| Mammalian lifespan extension (animal) | A | NIA ITP, Nature 2009; three labs, both sexes, late-life start |
| Autophagy / cellular "repair mode" | B | mTORC1 inhibition – a well-established mechanism |
| Safety at longevity dosing | C | PEARL RCT (weekly dosing): reasonably safe, but with real side effects |
| Immunosuppression (approved use) | A | FDA-approved 1999 for transplant; LAM 2015 |
| Human longevity / healthspan | F | No RCT has reached a longevity endpoint |
The mechanism is solid (B). The animal outcome is solid (A). The human outcome is absent (F). The register grades each link separately so that the strength of one doesn't spill over onto the next.
mTOR, the "mechanistic target of rapamycin", is the cell's nutrient-and-growth sensor. The protein was named after the drug, not the other way round. When mTOR is active, the cell grows and divides. When it is suppressed, the cell switches to conserving and repairing itself. Rapamycin binds a protein called FKBP12, and together they inhibit mTORC1, the growth-driving complex. The downstream effects map onto several hallmarks of ageing: more autophagy, less inflammaging, better mitochondrial function.
The longevity strategy depends on dosing schedule and selectivity. Intermittent low dosing aims to hit mTORC1 while largely sparing mTORC2, whose inhibition drives the glucose and immune side effects. That tightrope is what separates a "geroprotector" from an "immunosuppressant", and nobody has yet shown that it can be walked reliably in humans.
Rapamycin is a serious medicine. Its approved use is preventing transplant rejection: it suppresses the immune system on purpose. The PEARL trial found weekly dosing reasonably safe. Reported side effects included mouth ulcers, changes in glucose and lipids, and infection risk. That is why the register grades safety C, not "safe". Off-label longevity use requires clinical oversight and monitoring.
People also search "rapamycin for skin". The register has no graded skin outcome for rapamycin, so we make no claim here, either way. Without a graded outcome, any claim about the skin would be guesswork.
Rapamycin was isolated in the late 1960s from soil bacteria on Easter Island (Rapa Nui), which gave it its name. It has been an antifungal, a transplant drug, an anticancer agent and now the flagship of longevity research.
Does rapamycin extend lifespan? In mice, yes: grade A, the strongest result in the register. In humans, it is not shown: grade F.
Is rapamycin safe for longevity use? The PEARL trial found weekly dosing reasonably safe, but not benign. It is an immunosuppressant, and its side effects include mouth ulcers, metabolic changes and infection risk.
Is rapamycin legal? It is an approved prescription drug (sirolimus). Longevity use is off-label and needs a prescriber.
What would change the F? A human randomised trial with a genuine longevity or healthspan endpoint. None has succeeded yet. That is the field's central open question.
Does Vallydia publish doses? No.
Rapamycin is the most credible candidate longevity drug we have, and still a candidate. The animal evidence earns its A, and the human evidence earns its F. Anyone who quotes the first grade without the second is selling something.
The best mouse result in gerontology still needs a human trial.
See also NAD and NMN in skincare. Vallydia does not sell, supply or link to rapamycin.
How we separate evidence levels: how we grade · how we grade.
Vallydia sells its own cosmetic serums, and some ingredients discussed here belong to the same categories as those products. Assessments are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Brand and trade names appearing in these articles are the property of their respective owners and are used only to identify the product or ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor. Where we judge a claim, we are judging the published evidence for that claim — not making a statement about the company that makes it.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.